BioCryst Pharmaceuticals
BCRX
120 hedge funds and large institutions have $439M invested in BioCryst Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 17 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 28
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
14% more capital invested
Capital invested by funds: $384M → $439M (+$54.6M)
4% more funds holding
Funds holding: 115 → 120 (+5)
1.07% less ownership
Funds ownership: 85.89% → 84.81% (-1.1%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
77% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $4.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$23.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$11.7M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.33M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.38M |
| 5 |
DM
Deerfield Management
New York
|
+$7.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.82M |
| 2 |
D.E. Shaw & Co
New York
|
-$3.05M |
| 3 |
Goldman Sachs
New York
|
-$2.89M |
| 4 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$2.35M |
| 5 |
PC
Paulson & Co
New York
|
-$1.94M |
BCRX Hedge Fund Activity: Q3 2017 in Review
120 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2017, worth a combined $439M — up 14% from $384M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BCRX positions and 17 closed out — a net gain of 5 holders — while 42 added to existing stakes and 28 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $23.2M. The largest seller was State Street, cutting an estimated $4.82M.
- 120 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2017, up from 115 in Q2 2017.
- Funds reported $439M of BioCryst Pharmaceuticals stock for Q3 2017, up 14% quarter-over-quarter.
- 22 funds opened new BioCryst Pharmaceuticals positions in Q3 2017 and 17 closed out, a net change of +5 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2017 was Janus Henderson Group, an estimated $23.2M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2017 was State Street, an estimated $4.82M sold.
Based on aggregated 13F filings for Q3 2017.